{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:14:49Z","timestamp":1756901689550,"version":"3.44.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Iguratimod is a novel oral disease-modifying antirheumatic drug (DMARD) utilised for rheumatoid arthritis, characterised by a favourable safety profile and infrequent instances of hypersensitivity, predominantly mild and cutaneous in nature. This report describes what appears to be the first reported case of severe, noncutaneous anaphylaxis following a first oral dose of iguratimod. A 37-year-old woman with seropositive rheumatoid arthritis, previously stable on methotrexate, experienced acute respiratory distress, hypotension, and new-onset atrial fibrillation within 3\u00a0hours of her initial iguratimod dose. She had never experienced a medication allergy before. Examination indicated significant hypoxia and cardiovascular instability. Anaphylaxis was validated by increased serum tryptase levels. Immediate treatment included injectable epinephrine, corticosteroids, fluid resuscitation, and mechanical ventilation. Electrical cardioversion was necessary to treat atrial fibrillation. The patient was stabilised with intensive care and was discharged without complications. This case demonstrates a rare but dramatic adverse reaction to iguratimod, emphasising the necessity of including anaphylaxis in the differential diagnosis of acute cardiorespiratory collapse, even in the absence of skin signs. Clinicians must recognise that novel immunomodulatory drugs may provoke severe allergic reactions and ensure that suitable precautions and emergency protocols are established prior to commencing such therapies.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf053","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T12:36:33Z","timestamp":1755174993000},"source":"Crossref","is-referenced-by-count":0,"title":["Life-threatening anaphylaxis after first dose of Iguratimod"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6622-5969","authenticated-orcid":false,"given":"Bodhisatwa","family":"Choudhuri","sequence":"first","affiliation":[{"name":"Department of Critical Care & Rheumatology, Parkview Super-specialty Hospital , Kolkata ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025090110371019100_ref1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"volume-title":"Emergency Treatment of Anaphylaxis: Guidelines for Healthcare Providers","author":"Resuscitation Council UK","key":"2025090110371019100_ref2"},{"key":"2025090110371019100_ref3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025090110371019100_ref4","first-page":"129","article-title":"Hypersensitivity reactions during treatment with biological agents","volume":"34","author":"Puxeddu","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090110371019100_ref5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025090110371019100_ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jaip.2018.06.010","article-title":"Drug-induced anaphylaxis documented in electronic health records","volume":"7","author":"Dhopeshwarkar","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025090110371019100_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/310628","article-title":"Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2025090110371019100_ref8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025090110371019100_ref9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025090110371019100_ref10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090110371019100_ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24586","article-title":"Allergic skin rash caused by Iguratimod: a report of two cases","volume":"14","author":"Lu","year":"2022","journal-title":"Cureus"},{"key":"2025090110371019100_ref12","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.3390\/ijms25147666","article-title":"Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies","volume":"25","author":"Yasmeen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025090110371019100_ref13","doi-asserted-by":"publisher","first-page":"e41836","DOI":"10.1016\/j.heliyon.2025.e41836","article-title":"Human immune system: exploring diversity across individuals and populations","volume":"11","author":"Hoang Nguyen","year":"2025","journal-title":"Heliyon"},{"key":"2025090110371019100_ref14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/14397595.2019.1649229","article-title":"Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: post-hoc analysis of an all-case post-marketing surveillance study of iguratimod","volume":"30","author":"Ishiguro","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2025090110371019100_ref15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.anai.2022.08.996","article-title":"Tryptase in type I hypersensitivity","volume":"130","author":"Michel","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025090110371019100_ref16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1081-1206(10)62923-7","article-title":"Interleukin 6 and C-reactive protein levels in patients with acute allergic reactions: an emergency-department\u2013based study","volume":"87","author":"Lin","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025090110371019100_ref17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/cells10071697","article-title":"Tuning IgE: IgE-associating molecules and their effects on IgE-dependent mast cell reactions","volume":"10","author":"Ando","year":"2021","journal-title":"Cells"},{"key":"2025090110371019100_ref18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2500\/aap.2019.40.4274","article-title":"Classification of hypersensitivity reactions","volume":"40","author":"Dispenza","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"2025090110371019100_ref19","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"2025090110371019100_ref20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3238\/arztebl.2016.0834","article-title":"The differential diagnosis of dyspnea","volume":"113","author":"Berliner","year":"2016","journal-title":"Dtsch Arztebl Int"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf053\/64044154\/rxaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf053\/64044154\/rxaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf053\/64044154\/rxaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T14:37:19Z","timestamp":1756737439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf053\/8234319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf053","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf053"}}